论文部分内容阅读
目的探讨运动相关蛋白MRP-1/CD9在上皮性卵巢癌组织中的表达及临床意义。方法2004年1~11月中国医科大学附属第二医院应用半定量RT-PCR方法,检测MRP-1/CD9mRNA在36例上皮性卵巢癌、6例交界性卵巢肿瘤、8例良性上皮性卵巢肿瘤和8例正常卵巢组织中的表达。结果MRP-1/CD9mRNA在上皮性卵巢癌和交界性卵巢肿瘤组织中的表达率和表达强度分别为(33.3%,0.63±0.47)和(66.7%,1.10±0.40),与正常卵巢(100%,1.66±0.31)和卵巢良性肿瘤(100%,1.52±0.29)相比明显降低(P<0.05),其在卵巢癌中的表达率和表达强度均与肿瘤分期呈负相关(P<0.05),而与组织分级和病理类型无关(P>0.05)。结论MRP-1/CD9的表达缺失在上皮性卵巢癌的发生、发展、浸润过程中起重要的作用,可作为卵巢癌生物学行为的重要指标。
Objective To investigate the expression of MRP-1 / CD9 in epithelial ovarian cancer and its clinical significance. Methods From January to November 2004, the Second Affiliated Hospital of China Medical University used semi-quantitative RT-PCR to detect the expression of MRP-1 / CD9 mRNA in 36 cases of epithelial ovarian cancer, 6 cases of borderline ovarian tumor, 8 cases of benign epithelial ovarian tumor And 8 cases of normal ovarian tissue expression. Results The positive rate and expression of MRP-1 / CD9 mRNA in epithelial ovarian and borderline ovarian tumors were (33.3%, 0.63 ± 0.47) and (66.7%, 1.10 ± 0.40) , 1.66 ± 0.31) and ovarian benign tumor (100%, 1.52 ± 0.29 respectively) (P <0.05), and the expression rate and the expression intensity in ovarian cancer were negatively correlated with tumor stage (P0.05) , But not with histological grade and pathological type (P> 0.05). Conclusion The lack of MRP-1 / CD9 expression plays an important role in the development, progression and invasion of epithelial ovarian cancer, and may be used as an important indicator of the biological behavior of ovarian cancer.